Bringing Cure...Building Hope...
Home | Blog | Events
Pharma legitimate consultant and facilitator in Delhi India

ICLUSIG (ponatinib) tablets for oral use Initial U.S. Approval: 2012. Available In India

ICLUSIG (ponatinib tablets) is used for the treatment of patients with cancer (chronic lymphocytic leukemia-CLL, small lymphocytic lymphoma-SLL, acute myeloid leukemia-AML. ICLUSIG (ponatinib tablets) can be imported for personal use under "patient name basis" treatment in India. For this applicant is required to make an request application with required document. IPN, New Delhi will do the necessary process to obtain permission from Drugs Controller General (India) to import.

Generic Name: ponatinib Brand Name: ICLUSIG
ICLUSIG (ponatinib tablets) is used for the treatment of patients with cancer (chronic lymphocytic leukemia-CLL, small lymphocytic lymphoma-SLL, acute myeloid leukemia-AML.

Therapeutic indications and Usage Iclusig is a kinase inhibitor indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.
This indication is based upon response rate. There are no trials verifying an improvement in disease-related symptoms or increased survival with Iclusig.
If you have any questions about your illness, talk to your doctor
Source Details: Patient Information

Patient Name Basis Treatment IPN, New Delhi can facilitate patient to import of "ICLUSIG (ponatinib) tablets" in small quantities for personal use. For this applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP).

Healthcare Professional In India If you have any question, please email IPN Support Team or Call Indian Pharma Network for ICLUSIG (ponatinib) tablets price list or cost in India. on
Mr. Tarun:- +91 9891 296 838
Mr. Neeraj:- +91 9811 747 774

Indian Pharma Network, New Delhi. India

IPN, Delhi are legitimate consultant and facilitator in India, group of highly qualified pharma professionals.
Specialized in Oncology and other pharma products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Mumbai | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur | Punjab | Chandigarh
Our Overseas Network Uk | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Saudi Arabia | South Africa

ICLUSIG (ponatinib)injection
Note:-

We are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.

Facts of ICLUSIG (ponatinib) tablets


Iclusig is a kinase inhibitor indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy. This indication is based upon response rate. There are no trials verifying an improvement in disease-related symptoms or increased survival with Iclusig.

Source content : www.accessdata.fda.gov

IPN, New Delhi can facilitate patient to import of "ICLUSIG (ponatinib) tablets" in small quantities for personal use. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.

For procurement cost of ICLUSIG (ponatinib) tablets in India, Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the ICLUSIG (ponatinib) tablets medicine cost price in India.

The order for ICLUSIG (ponatinib) tablets will be confirmed only after
1. submitting Form 12A, along with the prescription of the Registered Medical Practitioner (RMP).
2. Permission from obtained from the office of the Drugs Controller General (India).
3. Availability of ICLUSIG (ponatinib) tablets from authorised distributor.

Ponatinib (trade name Iclusig, previously AP24534) is an oral drug developed by ARIAD Pharmaceuticals for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL). It is a multi-targeted tyrosine-kinase inhibitor. Some forms of CML, those that have the T315I mutation, are resistant to current therapies such as imatinib. Ponatinib has been designed to be effective against these types of tumors.

Ponatinib was approved by the US FDA on December 14, 2012, for patients with resistant or intolerant CML and Ph+ ALL, based on results of the PACE phase II trial reported days earlier at the annual ASH meeting. Because the approval was under the FDA Accelerated Approval program the applicant was required to carry out additional studies. Based on these additional studies, the FDA granted in 2016 full approval and updated the label to include patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia for whom no other tyrosine kinase inhibitor therapy is indicated. Approval was also granted for T315I-positive and T315I-positive Philadelphia chromosome positive acute lymphoblastic leukemia.

ICLUSIG® (ponatinib) tablets , for oral use Initial U.S. Approval: 2012

• 45 mg taken orally once daily with or without food
• Modify or interrupt dosing for hematologic and non-hematologic toxicity.

For ICLUSIG (ponatinib)Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details

FDA Approves Ponatinib To Treat Adult Patients with Resistant/Intolerant Chronic-Phase CML For More Details

Takeda to Present Positive Primary Analysis from Phase 2 OPTIC Trial of ICLUSIG® (ponatinib), Reinforcing Ability to Address Gaps in Care for Chronic-Phase CML For More Details

Step 1. Send a request for your medicine online:- Applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP).

Step 2. Verification of documents:- We verify your a prescription and necessary documents to import drugs in small quantities for personal use.

Step 3. Permission to Import:- After getting approval of Drugs Controller General (India), we start the process to import of drugs as mentioned in prescription for personal use.

Step 4. We source your medicine:- Our expert sourcing team work with our global network of suppliers to find you the best price. Once we have found you the lowest possible cost for your medicine, we will present you with a final offer for your approval.

Step 5. Delivery of medicine:- After you have accepted our offer, our experienced logistics team will arrange all the shipping and transportation of your medicine.

Doctor’s Prescription –
We would require prescription from Registered Medical Practitioner (RMP) stating product name, dosage, duration of treatment and diagnosis.

Patient’s Medical history –
We would require all test reports and medical reports of the patient for last 3 months.

Patient’s Identity card –
We will require scan copy of patient’s identity card and proof of residence to initiate documentation process.

Almost all countries across the world have provisions for granting access to drugs prior to marketing approval for personal use for patients who have exhausted all other treatment options available in their country. Indian Pharma Network, New Delhi can help patients in accessing/importing Ant-cancer medicines, unapproved in their home country against a legitimate prescription and in conformity with all local laws and regulations of their home country.

Send your query to find out -
ICLUSIG (ponatinib) price in South East Asia – China (Beijing, Chongqing, Shanghai, Tianjin and Shenzhen), Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong.
ICLUSIG (ponatinib) price in United Arab Emirates – Iraq, Iran, Saudi Arabia, Jordan.
ICLUSIG (ponatinib) price in North America – Mexico.
ICLUSIG (ponatinib) price in South America – Argentina, Brazil, Chile, Colombia, Peru, Venezuela.
ICLUSIG (ponatinib) price in Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia.
ICLUSIG (ponatinib) price in Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia.
ICLUSIG (ponatinib) price in African Countries – Algeria, Mauritius, Uganda, Zimbabwe.
ICLUSIG (ponatinib) price in Australia and New Zealand.

Your order will be shipped to you by our partner couriers, such as DHL, UPS and specialised cold chain couriers. If you would like your order to be shipped by a specific courier, please inform us when you place the order. Our standard delivery time varies from 5 to 10 working days. The shipping cost depends on the medicine and the destination country. After making an enquiry, you will receive a detailed quote that includes the shipping costs.

Get Access To FDA Approved Drug ICLUSIG (ponatinib) tablets In India

Indian Pharma Network (IPN), Delhi India is a leading Pharmaceutical Distributor / Supplier / Exporter / Importer of Anti-Cancer Medicines, used in chronic myelogenous leukemia-CML, acute lymphoblastic leukemia-ALL treatment. Brand Name "ICLUSIG (ponatinib) tablets" or Generic Name "Ponatinib tablets" can be imported for personal use under "patient name basis" treatment in Delhi, Noida, Gurgaon, Mumbai, Chennai, Kolkatta, Bangalore, Jaipur, Chandigarh India. Contact us at urgent@indianpharmanetwork.co.in or call/WhatsApp at +91 9891296838 / 9811747774 to get access as per norms.